GenrAb Closes Seed Round for Lead Therapy
GenrAb, Inc. has closed its seed financing round to accelerate development of its lead therapy, TGM-010, a first-in-class, fully-human neuroprotective antibody. Designed to cross the blood-brain barrier and target stressed neurons, TGM-010 is the first in GenrAb’s pipeline of novel neurotherapeutics. Backed by proprietary immunogenetic models, GenrAb is leveraging the human immune system to discover powerful therapies. This funding will support the advancement of TGM-010 through IND and into clinical trials by 2026. 
GenrAb Closes Seed Round for Lead Therapy